Austin Kirschner, MD, PhD, discusses the recent US commercial launch of the PROSTOX Standard test and its potential to inform radiation treatment decisions for patients with prostate cancer. In the ...

PROSTOX Standard targets CFRT (37–45 fractions) and MHFRT (20–28 fractions), expanding a regimen-specific platform aimed at predicting late GU toxicity after EBRT in localized prostate cancer.

Oncologists discuss the importance of guidelines like NCCN and ASCO for navigating cancer treatment complexities and insurance challenges. What recent guideline updates or data have most influenced ...

Ezra J. Margolin, MD, highlights a recent study examining antibiotic prescribing patterns for patients presenting to the emergency department with kidney stones. In the following video, Ezra J.

The report highlights key trends in cancer treatment and outcomes, including detailed analyses across 3 cancer types: prostate, esophageal, and melanoma. The ARID platform is evaluating the safety and ...

In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. In this ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...

"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes. Non–muscle invasive bladder cancer (NMIBC) often responds to induction ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...